NIH
Award Abstract #75N91019D00024-0-759102000009-1

ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH

Search for this grant on NIH site
Program Manager:
Active Dates:

Awarded Amount:

$67,359,812

Investigator(s):

BETH BASELER

Awardee Organization:

LEIDOS BIOMEDICAL RESEARCH, INC.
Maryland

Funding ICs:

National Institute of Allergy and Infectious Diseases (NIAID)

Abstract:

This funding supports INSIGHT Protocol Number: 013, Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC). It is an international multicenter, adaptive, randomized double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of anti-coronavirus hyperimmune intravenous immunoglobulin for the treatment of adult hospitalized patients at the onset of clinical progression of COVID-19.

Back to Top